Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin

Intern Emerg Med. 2018 Oct;13(7):1089-1091. doi: 10.1007/s11739-018-1886-y. Epub 2018 Jun 12.

Authors

Elisa Maria Fiorelli¹, Roberta Elisa Rossi²; GrAM (Gruppo di Autoformazione Metodologica)

Affiliations

¹ Department of Internal Medicine, Fondazione IRCSS Ca' Granda, Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122, Milano, Italy. elisa.fiorelli@unimi.it.
² Department of Gastroenterology and Endoscopy, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico and Department of Pathophysiology and Organ Transplant, Università degli Studi di Milano, Milan, Italy.

PMID: 29948831
DOI: 10.1007/s11739-018-1886-y

No abstract available

Publication types

Comment

MeSH terms

Anticoagulants
Heparin
Heparin, Low-Molecular-Weight*
Humans
Pyridines
Thiazoles
Venous Thromboembolism*
Venous Thrombosis

Substances

Anticoagulants
Heparin, Low-Molecular-Weight
Pyridines
Thiazoles
Heparin
edoxaban